1. Pink Sheet
  2. >>Agency Leadership

Plan B Decision May Offer FDA Best Political Protection Available

 
• By Nielsen Hobbs

Assuming that sexually charged products such as Teva’s emergency contraceptive remain subject to political decision-making, the explicit heavy hand of the HHS secretary in the OTC switch ruling may be the best approach for FDA and the Rx industry, especially considering the alternatives.

The dust generated by the decision to reject the over-the-counter switch of Teva Pharmaceuticals USA Inc.’s emergency contraceptive Plan B One Step (levonorgestrel 1.5 mg) will take a long time to settle, but the good news for pharmaceutical companies is that process was about as clean as it could be from industry perspective.

To many, the decision by Department of Health and Human Services Secretary Kathleen Sebelius to overrule FDA Commissioner Margaret Hamburg...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Agency Leadership

Kennedy Maintains mRNA Negativity Even When Couched As Trump Success

 
• By Sarah Karlin-Smith

The Health and Human Services Secretary's Sept. 4 appearance at the Senate Finance Committee also revealed more Republicans are souring on his vaccine policies, although most still support him.

US FDA Compounding Advisory Panel Hit Hardest By Recent Purges

 
• By Sarah Karlin-Smith

A Pink Sheet review found 10 FDA advisory panel members recently pulled off committees despite having time left in their appointed terms.

Rare Disease Drugs Pose Major Challenge For Brazil, Says ANVISA’s New Chief

 
• By Francesca Bruce

ANVISA, the Brazilian medicines regulator, has a new president, Leandro Pinheiro Safatle, who says that public private partnerships could help counter the impact of US tariffs on the pharmaceutical industry.

Offit’s VRBPAC Departure Raises Questions About Another HHS Panel Revamp

 
• By Sarah Karlin-Smith and Derrick Gingery

Offit, an outspoken critic of the Trump Administration's vaccine agenda, is no longer slated to serve two more years on the FDA's Vaccines and Related Biologics Products Advisory Committee.

More from Pink Sheet

EU Critical Medicines Act May Include Investigational Products & Mandatory Redistribution Measure

 
• By Neena Brizmohun

The inclusion of investigational drugs in the Critical Medicines Act and new provisions on stockpiling are among the raft of amendments the European Parliament has made to the draft legislation.

EU HTA Regulation: Key Gaps Identified In Support For Small Companies And Experts

 
• By Eliza Slawther

A meeting between the European Commission and industry stakeholders has revealed several areas of importance and lessons learned in relation to the EU Health Technology Assessment Regulation, which began to apply to certain medicinal products this year.

89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency

 
• By Bridget Silverman

The US FDA’s unprecedented publication of 89 recent CRLs for unapproved products comes with a promise to release future letters more promptly.